BioMarin's Financial Performance Overview
In the recently concluded third quarter of 2024, BioMarin Pharmaceutical Inc. announced total revenues of $746 million, marking a robust 28% growth compared to the previous year. Adjusting for constant currency fluctuations, this revenue growth stands at an impressive 32%. For year-to-date 2024, the total revenues reached $2.11 billion, which is a 19% increase from the previous year.
Key contributors to this growth were evident in the performance of VOXZOGO, which alone observed a staggering 54% rise in revenue year-over-year in the third quarter. Moreover, the Enzyme Therapies portfolio saw an increase of 27% in revenues for the same period.
Earnings and Profitability Metrics
BioMarin reported a GAAP diluted earnings per share (EPS) of $0.55 for third quarter 2024, which signifies a monumental 162% improvement year-over-year. Additionally, the year-to-date GAAP diluted EPS reached $1.56, reflecting a 103% growth from the prior year.
In terms of non-GAAP diluted EPS, the company reported $0.91 for Q3 2024, a 98% increase, while the year-to-date non-GAAP diluted EPS is now at $2.60, up by 63% compared to the previous year.
Strategic Initiatives Driving Revenue Growth
Addressing investors, Alexander Hardy, President and CEO of BioMarin, emphasized the impact of strategic decisions made over the last nine months that fostered strong operational performance and enhanced revenue growth. The new corporate strategy focuses on innovation, growth, and a commitment to value, which was palpable in the strong financial results and clinical advancements for patient care.
Hardy highlighted that over 3,800 infants and children globally are now benefiting from VOXZOGO treatment, pointing out that many new patient enrollments are primarily in younger children under five years. This trend suggests a significant acknowledgment among families regarding the importance of early intervention in managing achondroplasia.
Advancements in Clinical Programs
During the quarter, BioMarin made notable advances in its CANOPY clinical program. This included progressing studies in five new indications for VOXZOGO, especially focusing on conditions like hypochondroplasia, with enrollment in the Phase 3 registration study anticipated to complete in the first half of 2025.
The company is also progressing well with promising therapies in its pipeline, such as BMN 351 for Duchenne Muscular Dystrophy and BMN 349 for Alpha-1 antitrypsin deficiency-associated liver disease.
Growth Commitment and Future Guidance
The company aims to achieve approximately $4 billion in total revenues by 2027, with a projected 40% non-GAAP operating margin starting in 2026. BioMarin also anticipates generating over $1.25 billion in operating cash flow annually from 2027 onwards and targets a mid-teen compound annual growth rate (CAGR) for total revenues through 2034.
Investing in Future Innovation
During the past quarter, BioMarin reaffirmed its long-term guidance on sustained growth, illustrating confidence in the sustained demand for VOXZOGO and reinforcing the expansion of its Enzyme Therapies. The company has committed to ongoing investments in innovation while striving to enhance profitability.
A significant factor in managing operational costs effectively includes an ongoing $500 million cost transformation program, which has positively impacted the company’s operational efficiency, reflected in expanded GAAP and non-GAAP operating margins.
Frequently Asked Questions
How much did BioMarin's revenue grow in the third quarter of 2024?
BioMarin reported a 28% year-over-year revenue growth, reaching $746 million for the third quarter of 2024.
What was the non-GAAP diluted EPS for Q3 of 2024?
The non-GAAP diluted EPS for Q3 2024 was $0.91, which indicates a 98% increase compared to the previous year.
Which therapy significantly drove revenue growth for BioMarin?
VOXZOGO was a significant contributor, showing a 54% revenue growth year-over-year during the third quarter.
What are BioMarin's revenue targets for 2027?
BioMarin aims to achieve about $4 billion in total revenues by 2027.
What kind of investment strategies does BioMarin plan for future growth?
BioMarin is committed to investing in innovation while maintaining a focus on expanding profitability through their various strategies, including their cost transformation program.
